Literature DB >> 33801474

Role of Provocable Brugada ECG Pattern in The Correct Risk Stratification for Major Arrhythmic Events.

Nicolò Martini1, Martina Testolina2, Gian Luca Toffanin2, Rocco Arancio3, Luca De Mattia4, Sergio Cannas2, Giovanni Morani2, Bortolo Martini2.   

Abstract

The so-called Brugada syndrome (BS), first called precordial early repolarization syndrome (PERS), is characterized by the association of a fascinating electrocardiographic pattern, namely an aspect resembling right bundle branch block with a coved and sometime upsloping ST segment elevation in the precordial leads, and major ventricular arrhythmic events that could rarely lead to sudden death. Its electrogenesis has been related to a conduction delay mostly, but not only, located on the right ventricular outflow tract (RVOT), probably due to a progressive fibrosis of the conduction system. Many tests have been proposed to identify people at risk of sudden death and, among all, ajmaline challenge, thanks to its ability to enhance latent conduction defects, became so popular, even if its role is still controversial as it is neither specific nor sensitive enough to guide further invasive investigations and managements. Interestingly, a type 1 pattern has also been induced in many other cardiac diseases or systemic diseases with a cardiac involvement, such as long QT syndrome (LQTS), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM) and myotonic dystrophy, without any clear arrhythmic risk profile. Evidence-based studies clearly showed that a positive ajmaline test does not provide any additional information on the risk stratification for major ventricular arrhythmic events on asymptomatic individuals with a non-diagnostic Brugada ECG pattern.

Entities:  

Keywords:  Brugada syndrome; ajmaline challenge; arrhythmogenic right ventricular cardiomyopathy; early repolarization syndrome; hypertrophic cardiomyopathy; long QT syndrome

Year:  2021        PMID: 33801474      PMCID: PMC7958847          DOI: 10.3390/jcm10051025

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  52 in total

Review 1.  Proposed diagnostic criteria for the Brugada syndrome.

Authors:  A A M Wilde; C Antzelevitch; M Borggrefe; J Brugada; R Brugada; P Brugada; D Corrado; R N W Hauer; R S Kass; K Nademanee; S G Priori; J A Towbin
Journal:  Eur Heart J       Date:  2002-11       Impact factor: 29.983

2.  A long lasting electrocardiographic history.

Authors:  Bortolo Martini; Andrea Nava
Journal:  Heart Rhythm       Date:  2010-06-20       Impact factor: 6.343

Review 3.  Abnormal expression of cardiac neural crest cells in heart development: a different hypothesis for the etiopathogenesis of Brugada syndrome.

Authors:  Marcelo Víctor Elizari; Raúl Levi; Rafael Salvador Acunzo; Pablo Ambrosio Chiale; María M Civetta; Marcela Ferreiro; Serge Sicouri
Journal:  Heart Rhythm       Date:  2006-11-10       Impact factor: 6.343

4.  Risk stratification in patients with Brugada syndrome without previous cardiac arrest – prognostic value of combined risk factors.

Authors:  Hideo Okamura; Tsukasa Kamakura; Hiroshi Morita; Koji Tokioka; Ikutaro Nakajima; Mitsuru Wada; Kohei Ishibashi; Koji Miyamoto; Takashi Noda; Takeshi Aiba; Nobuhiro Nishii; Satoshi Nagase; Wataru Shimizu; Satoshi Yasuda; Hisao Ogawa; Shiro Kamakura; Hiroshi Ito; Tohru Ohe; Kengo F Kusano
Journal:  Circ J       Date:  2014-11-26       Impact factor: 2.993

5.  Next Generation Sequencing and Linkage Analysis for the Molecular Diagnosis of a Novel Overlapping Syndrome Characterized by Hypertrophic Cardiomyopathy and Typical Electrical Instability of Brugada Syndrome.

Authors:  Ruggiero Mango; Andrea Luchetti; Raffaele Sangiuolo; Valentina Ferradini; Nicola Briglia; Emiliano Giardina; Fabrizio Ferrè; Manuela Helmer Citterich; Francesco Romeo; Giuseppe Novelli; Federica Sangiuolo
Journal:  Circ J       Date:  2016-03-09       Impact factor: 2.993

Review 6.  Low risk for arrhythmic events in asymptomatic patients with drug-induced type 1 ECG. Do patients with drug-induced Brugada type ECG have poor prognosis? (Con).

Authors:  Mitsuhiro Nishizaki; Harumizu Sakurada; Noriyoshi Yamawake; Akiko Ueda-Tatsumoto; Masayasu Hiraoka
Journal:  Circ J       Date:  2010-10-15       Impact factor: 2.993

7.  Comparison of Ajmaline and Procainamide Provocation Tests in the Diagnosis of Brugada Syndrome.

Authors:  Christopher C Cheung; Greg Mellor; Marc W Deyell; Bode Ensam; Velislav Batchvarov; Michael Papadakis; Jason D Roberts; Richard Leather; Shubhayan Sanatani; Jeffrey S Healey; Vijay S Chauhan; David H Birnie; Jean Champagne; Paul Angaran; George J Klein; Raymond Yee; Christopher S Simpson; Mario Talajic; Martin Gardner; John A Yeung-Lai-Wah; Santabhanu Chakrabarti; Zachary W Laksman; Sanjay Sharma; Elijah R Behr; Andrew D Krahn
Journal:  JACC Clin Electrophysiol       Date:  2019-03-27

8.  Prevalence of type 1 Brugada ECG pattern after administration of Class 1C drugs in patients with type 1 myotonic dystrophy: Myotonic dystrophy as a part of the Brugada syndrome.

Authors:  Philippe Maury; Mathieu Audoubert; Pascal Cintas; Anne Rollin; Alexandre Duparc; Pierre Mondoly; Ana-Maria Chiriac; Blandine Acket; Xinran Zhao; Jean Luc Pasquié; Christelle Cardin; Marc Delay; Marie Sadron; Didier Carrié; Michel Galinier; Jean-Marc Davy; Marie-Christine Arne-Bès; Franck Raczka
Journal:  Heart Rhythm       Date:  2014-07-09       Impact factor: 6.343

9.  Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome.

Authors:  Hiroshi Morita; Shiho Takenaka Morita; Satoshi Nagase; Kimikazu Banba; Nobuhiro Nishii; Yoshinori Tani; Atsuyuki Watanabe; Kazufumi Nakamura; Kengo Fukushima Kusano; Tetsuro Emori; Hiromi Matsubara; Kazumasa Hina; Toshimasa Kita; Tohru Ohe
Journal:  J Am Coll Cardiol       Date:  2003-11-05       Impact factor: 24.094

10.  Response to intravenous ajmaline: a retrospective analysis of 677 ajmaline challenges.

Authors:  Christian Veltmann; Christian Wolpert; Frederic Sacher; Philippe Mabo; Rainer Schimpf; Florian Streitner; Joachim Brade; Florence Kyndt; Juergen Kuschyk; Herve Le Marec; Martin Borggrefe; Vincent Probst
Journal:  Europace       Date:  2009-07-09       Impact factor: 5.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.